Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Delivers On Generic Fostair With UK Luforbec Launch

UK’s NHS Spends Around $250m Per Year On Asthma And COPD Treatment

Executive Summary

Having previously seen patent litigation with originator Chiesi dismissed, Lupin has realized plans to launch the first UK generic version of Fostair (beclometasone/formoterol), with the potential for significant cost savings for the UK’s National Health Service.

You may also be interested in...



Lupin Lines Up A Pair Of US Launches

India’s Lupin has launched its droxidopa rival to Northera in the US, in 100mg, 200mg and 300mg strengths. The company also launched the generic version of Horizon’s Duexis ibuprofen/famotidine 800mg/26.6mg tablets.

Cipla Builds On Albuterol Share As Investors Await FY23 US Revenue Delta

Cipla signals more US momentum with headroom for albuterol market share expansion, promising prospects for generic Brovana and strong launch line-up in FY23, but analysts also keep close eye on regulatory pre-approval inspection timelines.

Stada’s Thornton & Ross Rivals Seretide In UK

Stada’s Thornton & Ross UK subsidiary has launched a generic version of Seretide, known as Advair in the US, marking its first push into the respiratory arena.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel